Showing 1341-1350 of 5771 results for "".
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- Melt Pharmaceuticals Announces Positive Phase 3 Trial Results for MELT-300 Sedation Solutionhttps://modernod.com/news/melt-pharmaceuticals-announces-positive-phase-3-trial-results-for-melt-300-sedation-solution/2482552/Melt Pharmaceuticals announced positive topline results from its pivotal phase 3 trial of MELT-300. This novel, non-intravenous, non-opioid tablet is designed to provide effective sedation during cataract surgery. The phase 3 study, conducted under a Special Protocol Assessment (SPA) ag
- Emmecell Announces Advancements of Non-Surgical Cell Therapy for Corneal Edemahttps://modernod.com/news/emmecell-announces-advancements-of-non-surgical-cell-therapy-for-corneal-edema/2482551/Emmecell announced positive results from its US multicenter phase 1 trial evaluating EO2002, a non-surgical cell therapy for corneal edema. The randomized, double-masked trial showed significant improvement in patients’ best corrected visual acuity (BCVA), reduction in central cor
- Samsung Bioepis and Biogen Announce EC Approval of Eylea Biosimilar Opuvizhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ec-approval-of-eylea-biosimilar-opuviz/2482545/Samsung Bioepis and Biogen jointly announced that the European Commission (EC) has granted approval for Opuviz 40 mg/mL for injection in a vial. The biosimilar, also known as SB15, references the established treatment Eylea (aflibercept) and was developed by Samsung Bioepis. T
- AlloVir and Kalaris Announce Merger to Create Company Focused on Retina Diseasehttps://modernod.com/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina/2482532/AlloVir announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. "On behalf of the AlloVir board, I am thrilled that we have entered into this transformational merger agreement with Kalaris,”
- Genentech Announces Phase 4 Results for Vabysmo in Treating DME Among Underrepresented Populationshttps://modernod.com/news/genentech-announces-phase-4-results-for-vabysmo-in-treating-dme-among-underrepresented-populations/2482514/Genentech revealed promising 1-year findings from its phase 4 ELEVATUM study for Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racial and ethnic groups typically underrepresented in clinical trials. Results presented at the American Academy of Ophthalmology (AAO) 2024 annual m
- Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukoshttps://modernod.com/news/ripple-therapeutics-announces-evaluation-and-licensing-agreements-with-glaukos/2482502/Ripple Therapeutics announced a new evaluation and licensing agreement with Glaukos this week that aims to leverage Ripple’s patented technology platform to create sustained release implants of targeted therapeutics for both glaucoma and retinal diseases. Financial terms of the de
- Glaukos Announces Positive Phase 3 Results for Epioxa Corneal Cross-Linking Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-results-for-epioxa-corneal-cross-linking-therapy/2482495/Glaukos announced that its second phase 3 confirmatory pivotal trial for Epioxa (Epi-on), a next-generation corneal cross-linking therapy for the treatment of keratoconus, has met its primary efficacy endpoint. The trial demonstrated a statistically significant and clinically
- Bausch + Lomb Announces New Data and Events at the 2024 AAO Annual Meeting in Chicagohttps://modernod.com/news/bausch-lomb-announces-new-data-and-events-at-the-2024-aao-annual-meeting-in-chicago/2482493/Bausch + Lomb announced its upcoming presentations and educational events at the American Academy of Ophthalmology (AAO) annual meeting, taking place in Chicago from October 18-21, 2024. The company will showcase new scientific data on its eye health products and technologies, incl
- Annexon to Present New Phase 2 Data on ANX007 for Geographic Atrophy at AAO 2024https://modernod.com/news/annexon-to-present-new-phase-2-data-on-anx007-for-geographic-atrophy-at-aao-2024/2482491/Annexon will present new analyses from the completed phase 2 ARCHER trial of ANX007 for the treatment of geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The company will also showcase findings at the Eyecelerator conference, held in conjunction with AAO